Hikma Narrows Profit Forecast to $740M-$760M
The British drugmaker reiterated its 2% to 4% annual revenue growth target as branded demand in the Middle East and North Africa offsets injectables pressure.
Updated on Nov. 5, 2026 in Corporate Finance
Hikma Pharmaceuticals narrowed its full-year operating profit forecast to $740 million to $760 million, down from a previous range of $720 million to $770 million. The company reiterated its annual revenue growth target of 2% to 4%.
Why it matters
The narrower range signals greater confidence in near-term earnings as strong branded demand in the Middle East and North Africa offsets pressure in the injectables division. Chief Executive Said Darwazah has sought to reassure investors that the turnaround remains on track.
Hikma's updated full-year operating profit forecast is $740 million to $760 million, versus a prior range of $720 million to $770 million. The company reiterated its overall annual revenue growth target of 2% to 4%, with self-branded revenue expected to grow around 10% in 2026.
The players
Hikma Pharmaceuticals
A British multinational pharmaceutical company with major operations in the Middle East and North Africa and a significant injectables business.
Said Darwazah
The chief executive of Hikma Pharmaceuticals, who has sought to reassure investors that the company's turnaround is on track.
Rebecca Hall
A finance executive joining Hikma Pharmaceuticals as its finance chief in March.
The details
Hikma said demand in its branded business across the Middle East and North Africa remains strong, offsetting pressure in its injectables division, which is stabilising. The company's supply chain is positioned to ensure continuity of supply. Rebecca Hall is joining as finance chief in March.
Timeline
November 5, 2026: Hikma narrowed its annual profit forecast range.
March 2026: Rebecca Hall is set to join Hikma as finance chief.
2026: Self-branded revenue is expected to grow around 10%, while injectables revenue is expected to be broadly flat.
Market Dynamics
Hikma reiterated its 2% to 4% annual revenue growth target even as it narrowed its profit range, signaling that management is holding its longer-term growth framework steady. The pairing of a stable revenue target with a tighter earnings range points to confidence in the branded portfolio amid pressure in injectables.
Investors holding Hikma shares may see the narrower profit range as a signal of steadier earnings expectations for the year ahead. The projected flat injectables revenue and roughly 10% branded growth indicate where near-term performance is expected to come from.
The takeaway
Hikma's narrowed profit range and reiterated revenue target suggest management expects branded growth to carry the company while injectables stabilises. Investors may watch the March arrival of the new finance chief for any shift in how guidance is framed.
Further reading
For broader context on how companies manage guidance and investor expectations, explore Corporate Finance.
